ICASA 2017

December 4-9, 2017
Abidjan, Côte d’Ivoire

The ICASA 2017 theme was ‘Africa: Ending AIDS-delivering differently’ and aimed to engage the whole continent and all stakeholders in the post sustainable development goal (SDG) framework, especially in relation to reaching the UNAIDS target of 90-90-90.

DNDi participated at the event.

 

Satellite Session

Poster for the satellite session held at ICASA 2017 on Friday 8 DecemberThe role of point-of-care testing for early infant diagnosis and improved treatment options towards ending paediatric AIDS

Date: Friday, December 8, 2017

With the increased availability of robust point-of-care (POC) molecular technologies for early infant diagnosis (EID), ministries of health (MOHs), along with partners, have begun to scale-up routine POC testing in HIV programs to optimize laboratory networks and improve clinical outcomes. In addition, improved formulations of World Health Organization-recommended treatments are being introduced or are in the final stages of drug development. This session will present how new POC technologies are being scaled up within the diagnostic networks of select countries, as well as highlight new treatment options available for infants and young children, within the broader context of ending pediatric AIDS. Representatives from early adopter countries will share their perspectives on what is needed for a successful and sustainable path to scaling up POC technologies and new optimal pediatric treatments.

 

Session

Children and adolescents

Date: Saturday, December 9, 2017

Chair: Denis Tindyebwa, Executive Director, The African Network for Care of Children Affected by HIV/AIDS (ANECCA), Uganda

Prospective Study of Lopinavir Based ART for HIV-infected Children Globally (LIVING Study): Interim 48-week Effectiveness and Safety Results
Salami O*, Kekitiinwa A, Wamalwa D, Obimbo E, Musiime V, Waweru M, Ouattara G, Odhiambo S, Kyomuhendo F, Simon F, Lee J, Omollo R, Egondi T, Stallaert J.F, Oyaro P, Bukusi E, Mwanga J, Wasunna M, Andrieux-Meyer I, Lallemant M

 

Poster Session

Date: Wednesday, December 6, 2017

Assessing acceptance and acceptability of an innovative pediatric antiretroviral lopinavir/ritonavir pellet formulation
Onyango-Ouma W, Nöstlinger C, Marchal B, Nyamongo I, Salami O, Lallemant M, Nebot Giralt A, Lee J

* Presenting author

 

More information: